New Lifetime High Today: Portola Pharmaceuticals (PTLA)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Portola Pharmaceuticals ( PTLA) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Portola Pharmaceuticals as such a stock due to the following factors:

  • PTLA has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $21.0 million.
  • PTLA has traded 4,701 shares today.
  • PTLA is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in PTLA with the Ticky from Trade-Ideas. See the FREE profile for PTLA NOW at Trade-Ideas

More details on PTLA:

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. Currently there are 3 analysts that rate Portola Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Portola Pharmaceuticals has been 361,900 shares per day over the past 30 days. Portola has a market cap of $2.3 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.74 and a short float of 9.7% with 6.22 days to cover. Shares are up 57.5% year-to-date as of the close of trading on Thursday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Portola Shares Lower After Pricing Stock Offering - Biotech Movers

Norwegian Cruise Line, iRobot, Bank of America: 'Mad Money' Lightning Round

What's Getting In This Rally's Way: Cramer's 'Mad Money' Recap (Thurs 8/24/17)

These Biotech Stocks are BOOMING

Cramer: Don't Risk It All on a Small Biotech Unless You're Willing to Lose It All